Early N-acetylaspartate depletion is a marker of neuronal dysfunction in rats and primates chronically treated with the mitochondrial toxin 3-nitropropionic acid

被引:119
作者
Dautry, W
Vaufrey, F
Brouillet, E
Bizat, N
Henry, PG
Condé, F
Bloch, G
Hantraye, P
机构
[1] CEA, DSV, DRM, Serv Hosp Frederic Joliot,URA CNRS 2210, F-91401 Orsay, France
[2] Serv Hosp Frederic Joliot, Grp RMN, Orsay, France
关键词
N-acetylaspartate; H-1-MRS; 3-nitropropionic acid; striatum; neurodegeneration; Huntington disease;
D O I
10.1097/00004647-200005000-00005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
N-acetylaspartate (NAA) quantification by H-1-magnetic resonance spectroscopy has been commonly used to assess in vivo neuronal loss in neurodegenerative disorders. Here the authors used ex vivo and in vivo H-1-magnetic resonance spectroscopy in mt and primate models of progressive striatal degeneration induced by the mitochondrial toxin 3-nitropropionate (3NP) to determine whether early NAA depletions could also be associated with neuronal dysfunction. In rats that were treated for 3 days with 3NP and had motor symptoms, the authors found a significant decrease in NAA concentrations, specifically restricted to the striatum. No cell loss or dying cells were found at this stage in these animals. After 5 days of 3NP treatment, a further decrease in striatal NAA con-centrations was observed in association with the occurrence of dying neurons in the dorsolateral striatum. In 3NP-treated primates, a similar striatal-selective and early decrease in NAA concentrations was observed after only a few weeks of neurotoxic treatment, without any sign of ongoing cell death. This early decrease in striatal NAA was partially reversed after 4 weeks of 3NP withdrawal. These results demonstrate that early NAA depletions reflect a reversible state of neuronal dysfunction preceding cell degeneration and suggest that in vivo quantification of NAA H-1-magnetic resonance spectroscopy may become a valuable tool for assessing early neuronal dysfunction and the effects of potential neuroprotective therapies in neurodegenerative disorders.
引用
收藏
页码:789 / 799
页数:11
相关论文
共 37 条
  • [1] QUANTITATION OF PROTON NMR-SPECTRA OF THE HUMAN BRAIN USING TISSUE WATER AS AN INTERNAL CONCENTRATION REFERENCE
    BARKER, PB
    SOHER, BJ
    BLACKBAND, SJ
    CHATHAM, JC
    MATHEWS, VP
    BRYAN, RN
    [J]. NMR IN BIOMEDICINE, 1993, 6 (01) : 89 - 94
  • [2] Inhibition of N-acetylaspartate production: Implications for H-1 MRS studies in vivo
    Bates, TE
    Strangward, M
    Keelan, J
    Davey, GP
    Munro, PMG
    Clark, JB
    [J]. NEUROREPORT, 1996, 7 (08) : 1397 - 1400
  • [3] CHRONIC ADMINISTRATION OF MALONIC-ACID PRODUCES SELECTIVE NEURAL DEGENERATION AND TRANSIENT CHANGES IN CALBINDIN IMMUNOREACTIVITY IN RAT STRIATUM
    BAZZETT, TJ
    FALIK, RC
    BECKER, JB
    ALBIN, RL
    [J]. EXPERIMENTAL NEUROLOGY, 1995, 134 (02) : 244 - 252
  • [4] BEAL MF, 1993, J NEUROSCI, V13, P4181
  • [5] CFOS IMMUNOREACTIVITY IS ENHANCED WITH BIOTIN AMPLIFICATION
    BERGHORN, KA
    BONNETT, JH
    HOFFMAN, GE
    [J]. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1994, 42 (12) : 1635 - 1642
  • [6] Brouillet E, 1998, J NEUROCHEM, V70, P794
  • [7] CHRONIC MITOCHONDRIAL ENERGY IMPAIRMENT PRODUCES SELECTIVE STRIATAL DEGENERATION AND ABNORMAL CHOREIFORM MOVEMENTS IN PRIMATES
    BROUILLET, E
    HANTRAYE, P
    FERRANTE, RJ
    DOLAN, R
    LEROYWILLIG, A
    KOWALL, NW
    BEAL, MF
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (15) : 7105 - 7109
  • [8] Replicating Huntington's disease phenotype in experimental animals
    Brouillet, E
    Condé, F
    Beal, MF
    Hantraye, P
    [J]. PROGRESS IN NEUROBIOLOGY, 1999, 59 (05) : 427 - 468
  • [9] Serial 1H-NMR spectroscopy study of metabolic impairment in primates chronically treated with the succinate dehydrogenase inhibitor 3-nitropropionic acid
    Dautry, C
    Condé, F
    Brouillet, E
    Mittoux, V
    Beal, MF
    Bloch, G
    Hantraye, P
    [J]. NEUROBIOLOGY OF DISEASE, 1999, 6 (04) : 259 - 268
  • [10] DESTEFANO N, 1995, MAGN RESON MED, V34, P721